Thus, under pathological conditions observed in hypertension, it can be assumed that NRF2 would be deprived of CBP binding, and under these circumstances, insufficient ARE transcription would occur, preventing NRF2 from eliciting an overwhelming enough antioxidant response to counteract ROS. The gene discussed is NFE2L2; the disease is hypertensive disorder.